Implementing Proactive Management Strategies with Amivantamab in Clinical Practice: Expert Insights
Wade T. Iams, MD, provides clinical insights on proactive management strategies for patients receiving amivantamab for advanced EGFR-mutant NSCLC.
Video content above is prompted by the following:
- How do you incorporate proactive management strategies into your practice setting?
- What challenges have you faced when integrating proactive management strategies into the clinical practice setting?
- What tools/resources would be helpful in overcoming these?
Recent Videos
Related Content
Clayton K. Oakley, DO, MS, MA;Amulya Yellala, MD;Sunil Tulpule, MD;Robin High, MA;Apar Kishor Ganti, MD;Alissa S. Marr, MD
December 5th 2024Article
These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
